Nucleotide excision repair and anti-cancer chemotherapy

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 187-201

  Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DNA adduct; ERCC1; Nucleotide excision repair; Ovarian cancer; Platinum compounds

Indexed keywords

CANCER CHEMOTHERAPY; DNA REPAIR; DRUG RESISTANCE; ENZYME ACTIVITY; EXCISION REPAIR; GENE SPECIFIC REPAIR; MISMATCH REPAIR; NUCLEOTIDE; O 6 ALKYLTRANSFERASE;

EID: 0032444410     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_12     Document Type: Article

References (94)

1. Zwelling LA, Andersen T and Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and transplatinum(II)diamminedichloride in L1210 mouse leukemia cells and its relation to cytotoxicity. Cancer Res 39: 365-369.
2. Plooy ACM, van Diik M and Lohman PHM (1984) Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 44: 2043-2051.
3. Reed E (1990) Cisplatin, In Pinedo HM, Chabner BA and Longo DL (eds) Cancer Chemotherapy and Biological Response Modifiers Annual - Volume 11. Elsevier Science Publishers B.V., Amsterdam, pp. 90-96.
4. Friedberg EC, Walker GC and Siede W (1995) DNA Repair and Mutagenesis, ASM Press, Washington, D.C.
5. Pegg AE (1990) Mammalian O6alkylguanine-DNA alkyltransferase: regulation and importance of response to alkylating carcinogenesis and therapeutic agents. Cancer Res 50: 6119-6129.
6. Brent TP and Remack JS (1988) Formation of covalent complexes between human O alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res 16: 6779-6788.
7. Seeberg E, Eide L and Bjoras M (1995) The base excision repair pathway. Trends Biochem Sci 20: 391-397.
8. Doroshow JH (1996) Anthracyclines and anthracenediones, In BA Chabner and DL Longo (eds) Cancer Chemotherapy and Biotherapy Principles and Practice, Lippincott-Raven, Philadelphia, 2nd ed, pp. 409-434.
9. Klungland A and Lindahl T (1997) Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO Journal 16: 3341-3348.
10. Sancar A and Sancar GB (1988) Annu Rev Biochem 57: 29-67.
11. Drapkin R, Sancar A and Reinberg D (1994) Where transcription meets repair. Cell 77: 9-12.
12. Lee KB, Parker RJ and Reed E (1995) Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance. Cancer Letters 88: 57-66.
13. Mu D, Park C-H, Matsunaga T, Hsu D S, Reardon J T and Sancar A (1995) Reconstitution of human DNA Repair excision nuclease in a highly defined system. J Biol Chem 270: 2415-2418.
14. Mu D, Hsu DS and Sancar A (1996) Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 271: 8285-8294.
15. Shivji MKK, Kenny MK and Wood RD (1992) Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69: 367-374.
16. Sancar A (1994) Mechanisms of DNA excision repair. Science 266: 1954-1956.
17. Van Vuuren AJ, Appeldoorn E, Odijk H, Humbert S, Moncollin V, Eker AP, Jaspers NG, Egly JM and Hoeijmakers JH (1995) Partial characterization of the DNA repair protein complex containing the ERCC1, ERCC4, ERCC11, and XPF correcting activities. Mutation Res 337: 25-39.
18. Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA and Reed E (1993) Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutation Res 293: 151-160.
19. Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ and Reed E (1995) Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 55: 1261-1266.
20. Dabholkar MD, Berger MS, Vionnet JA, Overton L, Bostick-Bruton F, Yu JJ, Silber JR and Reed E (1996) Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Molecular Carcinogenesis 17: 1-7.
21. Karran P (1995) Appropriate partners make good matches. Science 268: 1857-1858.
22. Modrich P (1994) Mismatch repair, genetic stability, and cancer. Science 266: 1959-1960.
23. Drummond JT, Li G-M, Longley Mj and Modrich P (1995) Isolation of an hMSH2-pl60 heterodimer that restores DNA mismatch repair to tumor cells. Science 268: 1909-1912.
24. Palombo F, Gallinari P and laccarino I et al. (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268: 1912-1914.
25. Drummond JT, Anthoney A, Brown R and Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648.
26. Wang XW and Harris CC (1997) P53 Tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol 173: 247-255.
27. Harris LC, Remack JS, Houghton PJ and Brent TP (1996) Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 56: 2029-2032.
28. Kastan MB, Canman CE and Leonard CJ (1995) p53, Cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14: 3-xx.
29. Righetti SC, Torre GD and Pilotti S et al. (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693.
30. Wahl AF, Donaldson KL and Fairchild C et al. (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79.
31. Weeda G, van Ham RCA, Vermeulen W, Bootsma D, van der Eb AJ and Hoeijmakers JHJ (1990) A presumed DNA helicase encoded by ERCC3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. Cell 62: 777-791.
32. Park C-H and Sancar A (1994) Formation of a ternary complex by human XPA, ERCC1, and ERCC4 (XPF) excision repair proteins. Proc Natl Acad Sci USA 91: 5017-5021.
33. Li L, Elledge SJ, Peterson cA, Baises ES and Legerski RJ (1994) Specific association between the human DNA repair proteins XPA and ERCC1. Proc Natl Acad Sci USA 91: 5012-5016.
34. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D and Hoeijmakers JHJ (1992) ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 71: 939-953.
35. Van Duin M, Koken MHM, van den Toi J, ten Dijke P, Odijk H, Westerveld A, Bootsma D and Hoeijmakers JHJ (1987) Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 15: 9195-9213.
36. Reed E (1993) 'Platinum Analogs'; Section 7 of Chapter 18 - 'Anticancer Drugs', In De Vita VT, Hellman S and Rosenberg SA (eds) Cancer Principles and Practice of Oncology, Lippincott, Philadelphia, pp. 390-400.
37. Reed E, Dabholkar M and Chabner BA (1996) Platinum Analogues, In Chabner BA and Longo DL (eds) Cancer Chemotherapy (2nd Ed), Lippincott-Raven Publishers, Philadelphia, pp. 357-378.
38. Eastman A, Schulte N, Sheibani N and Sorenson CM (1988) Mechanisms of resistance to platinum drugs. In Nicolini M (ed) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Martinus Nijhoff Publishing, Boston, pp. 178-196.
39. Parker RJ, Eastman A, Bostick-Bruton F and Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772-777.
40. Dabholkar M, Parker R and Reed E (1992) Determinants of cisplatin sensitivity in non-malignant, non-drug-selected human T cell lines. Mutation Res, 274(1): 45-56.
41. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruto F, Muggia FM and Reed E (1992) Cisplatin-DNA adduct damage and repair in peripheral blood leukocytes: in vivo and in vitro. Environmental Health Perspectives 93: 53-59.
42. Godwin AK, Meister A and O'Dwyer PJ et al. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074.
43. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC and Ozols RF (1996) Glutathione and drug resistance. Cancer Invest 14: 158-168.
44. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A and Bohr VA (1991) Preferential DNA repair of cisplatinum lesions in active genes in CHO cells. J Biol Chem, 266: 7101-7107.
45. Zhen W, Link Jr CJ, O'Connor PM, Reed E, Parker RJ, Howell SB and Bohr VA (1992) Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin resistant human ovarian cancer cells. Mol and Cell Biol 12: 3689-3698.
46. Lee KB, Parker RJ, Bohr VA, Cornelison TC and Reed E (1993) Cisplatin sensitivity/resistance in UV-repair deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14:2177-2180.
47. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56(13): 3087-3090.
48. Li Q, Tsang B, Dabholkar M, Bostick-Bruton F and Reed E (1998) Cisplatin induces ERCC1 mRNA and ERCC1 protein in A2780/CP70 human ovarian cancer cells. Proc Am Assoc Cancer Res 39: 241, abst# 1649.
49. Dabholkar M, Vionnet J, Parker RJ, Bostick-Bruton F, Dobbins A and Reed E (1995) Expression of an alternatively spliced ERCC1 mRNA species, is related to reduced DNA repair efficiency in human T lymphocytes. Oncology Reports 2:209-214.
50. Yu JJ, Reed EL, Mu C, Bostick-Bruton F and Reed E (1997) Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods. Oncology Reports 4: 905-907.
51. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC and Reed E (1997) A nucleotide polymorphism in ERCC1 gene in human ovarian cancer cell lines and tumor tissues. Mutation Research Genomics 382: 13-20.
52. Yu JJ, Mu C, Dabholkar M, Bostick-Bruton F and Reed E (1998) Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. International J Molecular Med 1:617-620.
53. Dabholkar M, Vionnet JA, Bostick-Bruton F, Yu JJ and Reed E (1994) mRNA Levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Invest 94: 703-708.
54. Van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken HM, Hoeijmakers JH and Bootsma D (1986) Molecular characterization of the human excision repair gene ERCC-1 : cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO. Cell 44: 913-923.
55. Perkins AS and Vande Woude GF (1993) Principles of molecular cell biology of cancer; oncogenes, In De Vita VT, Hellman S and Rosenberg SA (eds) Cancer Principles and Practice of Oncology, Lippincott, Philadelphia, pp. 35-59.
56. Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D and Yuspa SH (1982) Antibodies elicited against cis-diamminedichloroplatinum (II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA 79: 6443-6447.
57. Fichtinger-Schepman AMJ, Dijt FJ, De Jong WH, van Oosterom AT and Berends F (1988) in vivo cisDiamminedichloroplatinum(II)-DNA adduct formation and removal as measured with immunochemical techniques, In Nicolini M (ed) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Martinus Nijhoff Publishing, Boston, pp. 32-46.
58. Reed E, Sauerhoff S and Poirier MC (1988) Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure - A novel use of graphite furnace spectrometry. Atomic Spectroscopy 9: 93-95.
59. Perera FP, Tang D, Reed E, Parker RJ, Warburton D, O'Neill P, Albertini R, Bigbee W, Santella R, Tsai W-Y, Simon-Cereijido G, Randall C, Bosl G and Motzer R (1992) Multiple biologic markers in testicular cancer patients treated with platinum-based chemotherapy. Cancer Res 52: 3558-3565.
60. Reed E, Yuspa SH, Zwelling LA, Ozols RF and Poirier MC (1986) Quantitation of cisplatin-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77: 545-550.
61. Reed E, Ozols RF, Tarone R, Yuspa SH and Poirier MC (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84: 5024-5028.
62. Reed E, Ozols RF, Tarone R, Yuspa SH and Poirier MC (1988) The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 9: 1909-1911.
63. Reed E, Ostchega Y, Steinberg S, Yuspa SH, Young RC, Ozols RF and Poirier MC (1990) An evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50: 2256-2260.
64. Gupta-Burt S, Shamkhani H, Reed E, Tarone R, Allegra CJ, Pai L and Poirier MC (1993) Correlation between patient response in ovarian, breast, and colon cancer and platinum drugDNA adduct formation. Cancer Epidemiology, Biomarkers and Prevention 2: 229-234.
65. Poirier MC, Reed E, Litterst CL, Katz D and Gupta-Burt S (1992) Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52: 149-153.
66. Reed E, Gupta-Burt S, Litterst CL and Poirier MC (1990) Characterization of the DNA damage recognized by an antiserum elicited against ris-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis 11:2117-2121.
67. Fichtinger-Schepman AMJ, van der Velde-Bisser SD, van Kijk-Knijnenburg HCM, van Oosterom AT, Bann RA and Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 50: 7887-7894.
68. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM and Berends F (1987) Cis-Diamminedichloroplatinum(II)induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cisdiamminedichloroplatinum(II). Cancer Res 47: 3000-3004.
69. Fichtinger-Schepman AMJ, van Oosterom AT and Lohman PHM et al. (1987) Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutation Res 190: 59-62.
70. Motzer RJ, Reed E, Tang D, Shamkhani H, Poirier MC, Tsai W-Y, Parker RJ, Perera F and Bosl G (1994) Platinum-DNA adducts assayed in leukocytes of germ cell tumor patients measured by atomic absorbance spectroscopy and enzyme linked immunosorbent assay. Cancer 73: 2843-2852.
71. Tang DL, Motzer RJ, Warburton D, O'Neill P, Albertini R, Bigbee W, Jensen RH, Bosl G and Perera FP (1992) A study of five biological markers and clinical response in 36 testicular cancer patients treated with platinum-based chemotherapy. Proc Am Assoc Cancer Res 33: 263, abst #1577.
72. Parker RJ, Gill I, Tarone R, Vionnet J, Grunberg S, Muggia F and Reed E (1991) Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 12: 1253-1258.
73. Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R and Muggia FM (1993) PlatinumDNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancy. Cancer Res 53: 3694-3699.
74. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmilz PI, Stoter G and Verweij J (1996). Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumor response in patients with solid tumors. Br J Cancer 73(12): 1569-1575.
75. Reed E and Dabholkar M (1996) Platinum-DNA adduct in vitro and in the clinic; comparisons of DNA damage levels and biologic effects. Environ Mol Mutagenesis 27(27): 56, 1996.
76. Reed E, Dabholkar M, Yunmbam MK and Jones L (1998) Platinum-DNA adduct in vitro and in the clinic. Proc Am Assoc Cancer Res, 39: 505, abst# 3436.
77. Parker RJ, Dimery IW, Dabholkar M, Vionnet J and Reed E (1993) Platinum-DNA adduct in head and neck cancer patients receiving cisplatin and carboplatin chemotherapy. Internation J Oncol 3: 331-335.
78. McWhir J, Selfridge J, Harrison DJ, Squires S and Melton DW (1993) Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nature Genetics 5: 217-224.
79. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E (1992) ERCC1 and ERCC2 expression in malig-nant tissues from ovarian cancer patients. J Nat'1 Cancer Inst 84: 1512-1517.
80. Yu JJ, Dabholkar M, Bennett W, Welsh JA, Mu C, Bostick-Bruton F, Vionnet JA and Reed E (1996) Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between p53, ERCC1 and XPA. International J of Oncology 8: 313-317.
81. Reed E (1996) Ovarian cancer: molecular abnormalities, In Bertino JR (ed) The Encyclopedia of Cancer, Academic Press, Inc., San Diego, pp. 1192-1200.
82. States JC and Reed E (1996) Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Letters 108: 233-237.
83. Metzger R, Leichman CG and Danenberg KD et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316.
84. Bitton RJ, Figg WD and Reed E (1995) A preliminary risk-benefit assessment of paclitaxel. Drug Safety 12: 196-208.
85. Parker RJ, Dabholkar M, Lee KB, Bostick-Bruton F and Reed E (1993) Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monog Nat'1 Cancer Inst 15: 83-88.
86. Citardi MJ, Rowinsky EK and Donehower RC (1990) Sequence-depandent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. Proc Am Assoc Cancer Res 31: 410, Abst #2431.
87. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J and Maher M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: Molecular rationale and early clinical results. Seminars in Oncology 22: 90-96.
88. Kohn EC, Sarosy G, Davis P, Christian M, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A and Reed E (1996) A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poorprognosis advanced-stage epithelial ovarian cancer. Gynecologic Oncol 62: 181-191.
89. Rowinsky EK, Gilbert MR and McGuire WP et al. (1991) Sequences of taxol and cisplatin; phase I/pharmacologic study. J Clin Oncol 9: 1692-1703.
90. Reed E, Sarosy G, Kohn E, Christian M, Link C, Davis P, Maher M and Jacob J (1996) A phase I study of paclitaxel and cytoxan in recurrent adenocarcinoma of the ovary. Gynecologic Oncology 61: 349-353.
91. Reed E (1996) The chemotherapy of ovarian cancer. PPO Updates 10(7): 1-12.
92. Dabholkar M and Reed E (1995) Letter to the Editor (related to #95, above). Cancer Res, 55: 3933-3934.
93. Dabholkar M, Vionnet J and Bostick-Bruton F et al. (1995) Nucleotide excision repair mediates clinical resistance to platinum compounds in human ovarian cancer. Proc Am Assoc Cancer Res 36: 217, Abst #1295.
94. Reed E, Dabholkar M, Thompson C and Bostick-Bruton F (1998) Evidence for 'order' in the appearance of mRNAs of nucleotide excision repair genes in human ovarian cancer tissues. Submitted.